BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Chinese Patent Office
Cantor Fitzgerald
Boehringer Ingelheim
Queensland Health
Farmers Insurance

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,422,368

« Back to Dashboard

Summary for Patent: 5,422,368

Title: Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
Abstract:The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
Inventor(s): Stjernschantz; Johan W. (Upsala, SE), Resul; Bahram (Upsala, SE)
Assignee: Kabi Pharmacia AB (Upsala, SE)
Application Number:07/986,943
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,422,368

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden8803110Sep 06, 1988
Sweden8803855Oct 28, 1988
PCT/SE89/00475Sep 06, 1989

International Patent Family for Patent: 5,422,368

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany68929435► Subscribe
Germany68929563► Subscribe
Denmark112190► Subscribe
Denmark175842► Subscribe
Denmark200401645► Subscribe
Denmark176053► Subscribe
European Patent Office0364417► SubscribeSPC/GB97/014United Kingdom► Subscribe
European Patent Office0364417► Subscribe97C0128France► Subscribe
European Patent Office0364417► Subscribe9690031-1Sweden► Subscribe
European Patent Office0364417► Subscribe97C0111Belgium► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: